Want to see FR:GNFT full AI Analyst Report?
Top Page
Genfit
(GNFT)
Select Model
Select Model
Rating:42Neutral
Price Target:
€8.00
▼(-44.06% Downside)
Action:Reiterated
Date:09/29/26
The score is driven primarily by weak financial performance (return to heavy losses, renewed cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited offset because the negative P/E reflects ongoing losses and there is no dividend support.
Positive Factors
2025 Revenue Growth
The sharp 2025 revenue rebound indicates that Genfit can generate meaningful transaction or partnership-related income when pipeline and diagnostic activities advance. If progress continues, stronger top-line performance could support development investment and improve strategic leverage with potential partners.
Negative Factors
Return to Heavy Losses
The return to substantial operating and net losses shows that recent revenue growth has not translated into durable profitability. Historical swings from strong profitability to losses also make earnings power difficult to forecast and increase dependence on future pipeline progress or transactions.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Growth
The sharp 2025 revenue rebound indicates that Genfit can generate meaningful transaction or partnership-related income when pipeline and diagnostic activities advance. If progress continues, stronger top-line performance could support development investment and improve strategic leverage with potential partners.
Read all positive factors
Genfit (GNFT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€413.16M
Dividend YieldN/A
Average Volume (3M)402.87K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth27.70%
EPS Growth-162.89%
CountryFR
Employees180
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.04
Shares Outstanding50,099,620
10 Day Avg. Volume551,832
30 Day Avg. Volume402,866
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside4.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)€86.71M
Genfit Business Overview & Revenue Model
Company Description
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibrano...
How the Company Makes Money
Genfit’s revenue model is primarily partnership- and transaction-based rather than driven by recurring product sales, reflecting its clinical-stage profile. Key sources of earnings have included: (1) payments under licensing and collaboration agre...
Genfit Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
28
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.02M | 65.43M | 67.00M | 28.57M | 20.20M | 80.07M |
| Gross Profit | 1.01M | 14.55M | 66.70M | 28.22M | 19.95M | 79.91M |
| EBITDA | -18.26M | -8.04M | 8.35M | -22.24M | -23.60M | 71.89M |
| Net Income | -102.13M | -85.97M | 1.51M | -28.89M | -23.72M | 67.26M |
Balance Sheet | ||||||
| Total Assets | 153.57M | 157.93M | 151.42M | 173.87M | 215.54M | 281.72M |
| Cash, Cash Equivalents and Short-Term Investments | 113.82M | 101.09M | 81.79M | 77.79M | 140.55M | 258.76M |
| Total Debt | 179.28M | 150.69M | 62.13M | 70.18M | 75.28M | 74.23M |
| Total Liabilities | 202.10M | 181.58M | 82.20M | 105.92M | 121.01M | 162.62M |
| Stockholders Equity | -49.51M | -23.64M | 69.22M | 67.95M | 94.53M | 119.10M |
Cash Flow | ||||||
| Free Cash Flow | 7.50M | -26.71M | 14.22M | -57.92M | -72.64M | 99.38M |
| Operating Cash Flow | 8.37M | -25.32M | 15.20M | -55.43M | -72.64M | 99.92M |
| Investing Cash Flow | -969.00K | -3.63M | -1.04M | 2.23M | -46.27M | -3.38M |
| Financing Cash Flow | -1.41M | 48.07M | -10.57M | -5.10M | -3.79M | -8.92M |
Genfit Technical Analysis
Negative
14.30
Price Trends
12.28
Negative
11.73
Negative
9.68
Negative
Market Momentum
-1.10
Positive
28.30
Positive
11.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Negative. The current price of 14.3 is above the 20-day moving average (MA) of 10.05, above the 50-day MA of 12.28, and above the 200-day MA of 9.68, indicating a bearish trend. The MACD of -1.10 indicates Positive momentum. The RSI at 28.30 is Positive, neither overbought nor oversold. The STOCH value of 11.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:GNFT.
Genfit Risk Analysis
Genfit disclosed 73 risk factors in its most recent earnings report. Genfit reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genfit Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €680.51M | -5.40 | -1625.48% | ― | -99.64% | 68.67% | |
46 Neutral | €7.20M | -0.35 | 33.88% | ― | ― | ― | |
44 Neutral | €6.91B | -16.77 | -85.88% | ― | ― | ― | |
42 Neutral | €413.16M | -4.06 | 279.22% | ― | 27.70% | -162.89% | |
41 Neutral | €21.39M | -1.23 | -100.77% | ― | 417.14% | 22.08% | |
41 Neutral | €17.39M | -0.48 | ― | ― | -19.02% | 10.39% |
* Healthcare Sector Average
FR:GNFT
Genfit
8.28
4.60
125.00%
FR:ABVX
Abivax SA
79.00
-3.10
-3.78%
FR:IVA
Inventiva
2.86
-0.92
-24.34%
FR:POXEL
Poxel SA
0.13
-0.30
-68.76%
FR:ALVAL
Valbiotis SA
0.60
-0.18
-22.82%
FR:MAAT
MaaT Pharma
0.92
-3.45
-78.90%
Genfit Corporate Events
Genfit Bolsters Liver Disease Platform as Iqirvo Royalties Surge and Cash Runway Extends Beyond 2028
Sep 28, 2026
Genfit reported cash and cash equivalents of €113.8 million at June 30, 2026, a level the company expects will fund operations beyond the end of 2028, underpinned by royalty financing and anticipated milestone inflows. First-half 2026 revenu...
Genfit Bolsters ACLF Pipeline With Acquisition of Nangibotide
Sep 14, 2026
Genfit has expanded its late-stage pipeline by acquiring nangibotide, a TREM‑1 pathway modulator, and plans to test it in acute-on-chronic liver failure, a key focus area for the company. The move builds on prior Phase 2 data in septic shock...
Genfit Secures Spot in Euronext SBF 120 and CAC Mid 60 Indices
Sep 11, 2026
Genfit will be added to the SBF 120 and CAC Mid 60 indices on Euronext Paris, reflecting a rise in its market capitalization, liquidity and visibility on the French stock market. The inclusion in these closely watched benchmarks is expected to bol...
Genfit to Present at H.C. Wainwright Global Investment Conference
Sep 10, 2026
Genfit said its management team will take part in the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, 2026, with a formal presentation and one-on-one meetings with investors. A replay of the presentation will be m...
Genfit Targets Billion‑Dollar MASH Diagnostics Market With NISTM Blood Tests
Sep 9, 2026
Genfit is sharpening its focus on non‑invasive diagnostics for MASLD and MASH, aiming to replace painful liver biopsies with scalable blood‑based tests that assess disease activity and fibrosis. The company’s NISTM platform sits ...
Genfit Targets Non‑Invasive MASH Diagnostics Growth After U.S. Reimbursement Win for NASHnext
Sep 3, 2026
Genfit will host a virtual key opinion leader event on September 9 to spotlight its proprietary non‑invasive diagnostic platform for metabolic dysfunction‑associated steatohepatitis, featuring hepatology expert Professor Vlad Ratziu. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.